{rfName}

Indexed in

License and use

Citations

6

Altmetrics

Analysis of institutional authors

Albero RAuthor

Share

May 22, 2024
Publications
>
Article
Hybrid Gold

Romidepsin and Afatinib Abrogate Jak-Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma.

Publicated to:Journal Of Investigative Dermatology. 144 (7): 1579-1589.e8 - 2024-01-01 144(7), DOI: 10.1016/j.jid.2023.12.010

Authors: Shih BB; Ma C; Cortes JR; Reglero C; Miller H; Quinn SA; Albero R; Laurent AP; Mackey A; Ferrando AA; Geskin L; Palomero T

Affiliations

Department of Medicine, Columbia University Medical Center, New York, New York, USA. - Author
Institute for Cancer Genetics, Columbia University, New York, New York, USA. - Author
Institute for Cancer Genetics, Columbia University, New York, New York, USA; Biomedical Research Institute August Pi y Sunyer (IDIBAPS), Barcelona, Spain. - Author
Institute for Cancer Genetics, Columbia University, New York, New York, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA. Electronic address: tp2151@cumc.columbia.edu. - Author
Institute for Cancer Genetics, Columbia University, New York, New York, USA; Regeneron Pharmaceuticals, Tarrytown, New York, USA. - Author
Institute for Cancer Genetics, Columbia University, New York, New York, USA; Regeneron Pharmaceuticals, Tarrytown, New York, USA; Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York, USA; Department of Pediatri - Author
See more

Abstract

Cutaneous T-cell lymphomas are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T-cells. A distinctive clinical feature of cutaneous T-cell lymphomas is their sensitivity to treatment with histone deacetylase inhibitors. However, responses to histone deacetylase inhibitor therapy are universally transient and noncurative, highlighting the need for effective and durable drug combinations. In this study, we demonstrate that the combination of romidepsin, a selective class I histone deacetylase inhibitor, with afatinib, an EGFR family inhibitor, induces strongly synergistic antitumor effects in cutaneous T-cell lymphoma models in vitro and in vivo through abrogation of Jak-signal transducer and activator of transcription signaling. These results support a previously unrecognized potential role for histone deacetylase inhibitor plus afatinib combination in the treatment of cutaneous T-cell lymphomas.

Keywords

AfatinibAnimalAnimalsAntineoplastic activityAntineoplastic combined chemotherapy protocolsApoptosisArticleCcar2 proteinCcnb2 proteinCcnd3 proteinCcny proteinCd28 antigenCd3 antigenCd4+ t lymphocyteCdnk1a proteinCell deathCell line, tumorCell viabilityCell viability assayCerdulatinibClinical articleClinical evaluationCombination therapyControlled studyCutaneous t cell lymphomaCutaneous t-cell lymphomaCutaneous t-cell lymphoma cell lineDepsipeptidesDrug approvalDrug effectDrug efficacyDrug potentiationDrug screeningDrug synergismDrug therapyEntinostatGandotinibGene expressionHigh throughput screeningHistone deacetylase inhibitorsHumanHuman cellHuman tissueHumansHut 78 cell lineIn vitro studyIn vivo studyInterleukin 15 receptor alphaInterleukin 2Interleukin 2 receptor betaInterleukin 6 receptorJak-stat signalingJanus kinaseJanus kinase 1Janus kinasesLymphoma, t-cell, cutaneousMaleMammalian target of rapamycinMetabolismMiceMocetinostatMouseNonhumanPacritinibPathologyPhosphatidylinositol 3 kinasePreclinical modelsRomidepsinRuxolitinibSignal transductionSkin neoplasmsSkin tumorStat proteinStat1 proteinStat5 proteinSynergistic effectTreatment indicationTumor cell lineXenograft model antitumor assaysYoung adult

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Journal Of Investigative Dermatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 7/94, thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology. Notably, the journal is positioned above the 90th percentile.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2025-08-02:

  • Scopus: 2

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-08-02:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 3.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 3 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 0.5.
  • The number of mentions on the social network X (formerly Twitter): 1 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: United States of America.